Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Theralase Technologies ( (TSE:TLT) ) is now available.
Theralase Technologies has reported preclinical in vitro results showing that combining its light-activated Ruvidar molecule with recombinant human interferon alpha-2b produces significantly higher bladder cancer cell kill than either treatment alone. The study in T24 human bladder cancer cells demonstrated a 50% to 65% increase in total cell kill when interferon was added after Ruvidar activation, indicating a strong additive effect across rising interferon doses.
Ruvidar directly destroys tumor cells in a way that stimulates both innate and adaptive immune responses, while interferon alpha-2b slows cancer growth, promotes cell death and enhances local immune activity in the bladder. Theralase says the data support its strategy to launch a combination clinical study in patients with high-risk BCG-unresponsive non-muscle invasive bladder cancer carcinoma in situ, aiming to improve efficacy and durability of response and potentially strengthen its position in the bladder cancer treatment landscape.
The most recent analyst rating on (TSE:TLT) stock is a Hold with a C$0.25 price target. To see the full list of analyst forecasts on Theralase Technologies stock, see the TSE:TLT Stock Forecast page.
Spark’s Take on TSE:TLT Stock
According to Spark, TipRanks’ AI Analyst, TSE:TLT is a Neutral.
The score is held down primarily by weak financial performance—very large losses versus a small and declining revenue base, ongoing cash burn, and substantial equity erosion. Technicals provide some support with strong recent momentum (price above major moving averages and positive MACD), but elevated RSI suggests the move may be stretched. Valuation remains unattractive due to negative earnings and no dividend yield.
To see Spark’s full report on TSE:TLT stock, click here.
More about Theralase Technologies
Theralase Technologies Inc. is a Toronto-based clinical-stage pharmaceutical company focused on developing energy-activated small molecules for the targeted destruction of cancer, bacteria and viruses. Its lead platform, including the light-activated molecule Ruvidar, is being advanced primarily in bladder cancer, with an emphasis on high-risk, BCG-unresponsive non-muscle invasive disease.
Average Trading Volume: 187,308
Technical Sentiment Signal: Strong Buy
Current Market Cap: C$73.26M
See more insights into TLT stock on TipRanks’ Stock Analysis page.